Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

This study is designed as a multi-cohort trial based on various patient biomarkers study with the potential to include new study treatment in the future. EGFR-sensitive mutation-positive patients with distant recurrence after adjuvant osimertinib treatment for EGFRm resectable SIB-IIIA NSCLC and scheduled to receive osimertinib plus chemotherapy will be enrolled in cohort 1. In this cohort, approximately 100 patients will be recruited from 25 sites in China. The enrolment period is planned to be approximately 16 months.

NCT Number	NCT07279935
Lead Sponsor	AstraZeneca
Conditions	Non-small Cell Lung Cancer
Enrollment	100 participants
Start Date	2026-05-26
Primary Completion	2030-05-18 (estimated)
Study Completion	2030-05-18 (estimated)
Updated on ClinicalTrials.gov	2026-06-01